Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Chemocentryx | History Defined

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why ChemoCentryx Shares Are Popping Off

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results.

ChemoCentryx: Q1 Earnings Insights

ChemoCentryx (NASDAQ:CCXI) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ChemoCentryx missed estimated earnings by 83.33%, reporting an EPS of $-0.55 versus an estimate of $-0.3.

ChemoCentryx's Earnings: A Preview

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.30.

inkl

Read news from The Economist, FT, and more,
with one subscription

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

ChemoCentryx's Return On Capital Employed Insights

ChemoCentryx's Return On Capital Employed Insights

ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million.

See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter. Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike…

Why ChemoCentryx Shares Are Falling

Why ChemoCentryx Shares Are Falling

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results.

Recap: ChemoCentryx Q4 Earnings

Recap: ChemoCentryx Q4 Earnings

ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Earnings Preview: ChemoCentryx

Earnings Preview: ChemoCentryx

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.50.

Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake?

Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake?

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.

Get all your
news in one place.

100's of premium titles.
One news app.

Why ChemoCentryx Shares Are Rising

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis.

ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis.

1

Organisations

Micron Technology

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play